amantadine has been researched along with Central Nervous System Diseases in 11 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In separate studies, drugs were administered at a dosage of 200 mg/day (52 volunteers) or 300 mg/day (196 volunteers) for 4." | 2.65 | Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. ( Adams, KF; Giordani, B; Gwaltney, JM; Hayden, FG; Van de Castle, RL, 1981) |
| "Amantadine use was associated with a significantly higher incidence of central nervous system adverse events than rimantadine use in this elderly population receiving influenza prophylaxis." | 1.31 | Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. ( Bertino, JS; Karl, M; Keyser, LA; Nafziger, AN, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayden, FG | 1 |
| Gwaltney, JM | 1 |
| Van de Castle, RL | 1 |
| Adams, KF | 1 |
| Giordani, B | 1 |
| Kanemitsu, K | 1 |
| Ikejima, H | 1 |
| Shimada, J | 1 |
| Keyser, LA | 1 |
| Karl, M | 1 |
| Nafziger, AN | 1 |
| Bertino, JS | 1 |
| Gilbert, JC | 1 |
| Gehlen, W | 1 |
| Douglas, RG | 1 |
| Mathé, G | 1 |
| Schwarzenberg, L | 1 |
| Amiel, JL | 1 |
| Pouillart, P | 1 |
| Hayat, M | 1 |
| de Vassal, F | 1 |
| Rosenfeld, C | 1 |
| Jasmin, C | 1 |
| Strong, DK | 1 |
| Eisenstat, DD | 1 |
| Bryson, SM | 1 |
| Sitar, DS | 1 |
| Arbus, GS | 1 |
| Schergna, E | 1 |
| Norris, FH | 1 |
| Braham, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
2 reviews available for amantadine and Central Nervous System Diseases
| Article | Year |
|---|---|
[Neurotoxicity of antiviral agents].
Topics: Acyclovir; Amantadine; Antiviral Agents; Central Nervous System Diseases; Ganciclovir; Humans; Riman | 1999 |
[Iatrogenic damage possibilities in the drug therapy of neurologic and psychiatric diseases].
Topics: Amantadine; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Central Nervous System Di | 1977 |
2 trials available for amantadine and Central Nervous System Diseases
| Article | Year |
|---|---|
Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.
Topics: Adamantane; Adult; Amantadine; Central Nervous System Diseases; Gastrointestinal Diseases; Humans; M | 1981 |
New experimental and clinical data on leukaemia immunotherapy.
Topics: Adolescent; Adult; Amantadine; Animals; Bacterial Vaccines; BCG Vaccine; Cell Line; Central Nervous | 1975 |
7 other studies available for amantadine and Central Nervous System Diseases
| Article | Year |
|---|---|
Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Cent | 2000 |
Diseases of the central nervous system. Pharmacological basis of treatment.
Topics: Amantadine; Analgesics, Opioid; Anticonvulsants; Blood-Brain Barrier; Central Nervous System Disease | 1975 |
Influenza: the disease and its complications.
Topics: Amantadine; Aspirin; Bacterial Infections; Bronchitis; Central Nervous System Diseases; Cross Infect | 1976 |
Amantadine neurotoxicity in a pediatric patient with renal insufficiency.
Topics: Adolescent; Amantadine; Central Nervous System Diseases; Creatine; Female; Graft Rejection; Hallucin | 1991 |
[Recent therapeutic conquests in extrapyramidal syndromes].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Amantadine; Athetosis; Brain Diseases; Central | 1970 |
Amantadine in Jakob-Creutzfeldt disease.
Topics: Amantadine; Amyotrophic Lateral Sclerosis; Central Nervous System Diseases; Creutzfeldt-Jakob Syndro | 1972 |
Jakob-Creutzfeldt disease: treatment by amantadine.
Topics: Aged; Amantadine; Central Nervous System Diseases; Creutzfeldt-Jakob Syndrome; Electroencephalograph | 1971 |